Elemento Lab

Publications

Found 391 results
Filters: First Letter Of Last Name is K  [Clear All Filters]
2015
Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.
Beltran H, Eng K, Mosquera JMiguel, Sigaras A, Romanel A, Rennert H, Kossai M, Pauli C, Faltas B, Fontugne J et al..  2015.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.. JAMA Oncol. 1(4):466-74.
2014
Erler P, Keutgen XM, Crowley MJ, Zetoune T, Kundel A, Kleiman D, Beninato T, Scognamiglio T, Elemento O, Zarnegar R et al..  2014.  Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer.. Surgery. 156(6):1342-50;discussion1350.
Erler P, Keutgen XM, Crowley MJ, Zetoune T, Kundel A, Kleiman D, Beninato T, Scognamiglio T, Elemento O, Zarnegar R et al..  2014.  Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer.. Surgery. 156(6):1342-50;discussion1350.
Erler P, Keutgen XM, Crowley MJ, Zetoune T, Kundel A, Kleiman D, Beninato T, Scognamiglio T, Elemento O, Zarnegar R et al..  2014.  Dicer expression and microRNA dysregulation associate with aggressive features in thyroid cancer.. Surgery. 156(6):1342-50;discussion1350.
Kasap C, Elemento O, Kapoor TM.  2014.  DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.. Nat Chem Biol. 10(8):626-8.
Kasap C, Elemento O, Kapoor TM.  2014.  DrugTargetSeqR: a genomics- and CRISPR-Cas9-based method to analyze drug targets.. Nat Chem Biol. 10(8):626-8.
Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC et al..  2014.  Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.. PLoS Genet. 10(9):e1004566.
Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC et al..  2014.  Histone methyltransferase MMSET/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation.. PLoS Genet. 10(9):e1004566.
de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF.  2014.  Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.. Cancer Biol Ther. 15(9):1239-47.
de Martino M, Zhuang D, Klatte T, Rieken M, Rouprêt M, Xylinas E, Clozel T, Krzywinski M, Elemento O, Shariat SF.  2014.  Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.. Cancer Biol Ther. 15(9):1239-47.
Chakravarty D, Sboner A, Nair SS, Giannopoulou E, Li R, Hennig S, Mosquera JMiguel, Pauwels J, Park K, Kossai M et al..  2014.  The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer.. Nat Commun. 5:5383.
Sandler VM, Lis R, Liu Y, Kedem A, James D, Elemento O, Butler JM, Scandura JM, Rafii S.  2014.  Reprogramming human endothelial cells to haematopoietic cells requires vascular induction.. Nature. 511(7509):312-8.
Kleiman DA, Beninato T, Sultan S, Crowley MJP, Finnerty B, Kumar R, Panarelli NC, Liu Y-F, Lieberman MD, Seandel M et al..  2014.  Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.. Ann Surg Oncol. 21 Suppl 4:S672-9.
Kleiman DA, Beninato T, Sultan S, Crowley MJP, Finnerty B, Kumar R, Panarelli NC, Liu Y-F, Lieberman MD, Seandel M et al..  2014.  Silencing of UCHL1 by CpG promoter hyper-methylation is associated with metastatic gastroenteropancreatic well-differentiated neuroendocrine (carcinoid) tumors.. Ann Surg Oncol. 21 Suppl 4:S672-9.
Diman NYS-G, Brooks G, Kruithof BPT, Elemento O, Seidman JG, Seidman CE, Basson CT, Hatcher CJ.  2014.  Tbx5 is required for avian and Mammalian epicardial formation and coronary vasculogenesis.. Circ Res. 115(10):834-44.
2013
De S, Shaknovich R, Riester M, Elemento O, Geng H, Kormaksson M, Jiang Y, Woolcock B, Johnson N, Polo JM et al..  2013.  Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity.. PLoS Genet. 9(1):e1003137.
Kumar R, DiMenna L, Schrode N, Liu T-C, Franck P, Muñoz-Descalzo S, Hadjantonakis A-K, Zarrin AA, Chaudhuri J, Elemento O et al..  2013.  AID stabilizes stem-cell phenotype by removing epigenetic memory of pluripotency genes.. Nature. 500(7460):89-92.
Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.
Béguelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SNing, Wang L, Ezponda T et al..  2013.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.. Cancer Cell. 23(5):677-92.
Bödör C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM et al..  2013.  EZH2 mutations are frequent and represent an early event in follicular lymphoma.. Blood. 122(18):3165-8.
Hess ME, Hess S, Meyer KD, Verhagen LAW, Koch L, Brönneke HS, Dietrich MO, Jordan SD, Saletore Y, Elemento O et al..  2013.  The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry.. Nat Neurosci. 16(8):1042-8.
Hess ME, Hess S, Meyer KD, Verhagen LAW, Koch L, Brönneke HS, Dietrich MO, Jordan SD, Saletore Y, Elemento O et al..  2013.  The fat mass and obesity associated gene (Fto) regulates activity of the dopaminergic midbrain circuitry.. Nat Neurosci. 16(8):1042-8.
Rafii S, Kloss CC, Butler JM, Ginsberg M, Gars E, Lis R, Zhan Q, Josipovic P, Ding B-S, Xiang J et al..  2013.  Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition.. Blood. 121(5):770-80.
Hatzi K, Jiang Y, Huang C, Garrett-Bakelman F, Gearhart MD, Giannopoulou EG, Zumbo P, Kirouac K, Bhaskara S, Polo JM et al..  2013.  A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters.. Cell Rep. 4(3):578-88.